Eli Lilly and Company (NYSE:LLY) Shares Bought by Gunderson Capital Management Inc.

Gunderson Capital Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 1.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 22,497 shares of the company’s stock after purchasing an additional 223 shares during the quarter. Eli Lilly and Company makes up 8.4% of Gunderson Capital Management Inc.’s investment portfolio, making the stock its largest holding. Gunderson Capital Management Inc.’s holdings in Eli Lilly and Company were worth $19,931,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. Capital Planning LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $262,000. CHURCHILL MANAGEMENT Corp acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company in the first quarter valued at $8,896,000. HighPoint Advisor Group LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $9,878,000. Finally, Leo Wealth LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $3,355,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $2.05 during trading on Wednesday, reaching $915.77. 648,965 shares of the company’s stock were exchanged, compared to its average volume of 3,013,804. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $870.35 billion, a PE ratio of 135.45, a PEG ratio of 2.78 and a beta of 0.42. The firm’s fifty day moving average price is $904.41 and its 200-day moving average price is $850.31.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on LLY shares. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Citigroup started coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research note on Monday, September 16th. BMO Capital Markets raised their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Finally, Guggenheim lifted their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.